Guardant Health, Inc. - Common Stock (NQ:GH)

184.08 +1.49 (+0.82%)

Delayed Quote Updated: 1:55 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Guardant Health, PacBio, Align Technology, QuidelOrtho, and Omnicell Shares Are Falling, What You Need To Know

February 23, 2026

A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court...

Via StockStory

Guardant Health Inc (NASDAQ:GH) Posts Strong Q4 Revenue Beat and Bullish 2026 Outlook ↗

February 19, 2026

Via Chartmill

Guardant Health (NASDAQ:GH) Surprises With Q4 CY2025 Sales

February 19, 2026

Diagnostics company Guardant Health (NASDAQ:GH) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 39.4% year on year to $281.3 million. The company’s full-year revenue...

Via StockStory

Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

February 19, 2026

From Guardant Health, Inc.

Via Business Wire

Earnings To Watch: Guardant Health (GH) Reports Q4 Results Tomorrow

February 17, 2026

Diagnostics company Guardant Health (NASDAQ:GH) will be reporting results this Thursday after market hours. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence Economy World Trade

3 Unprofitable Stocks Walking a Fine Line

February 15, 2026

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

Via StockStory

Small Caps Roar: Russell 2000 Surges as Cooling Inflation Ignites Rate Cut Hopes

February 13, 2026

In a decisive shift for equity markets, the small-cap heavy Russell 2000 index outperformed its large-cap peers on Friday, February 13, 2026, as investors cheered a cooler-than-expected Consumer Price...

Via MarketMinute

Topics Bonds ETFs Economy

Guardant Health to Participate in Upcoming Investor Conferences

February 03, 2026

From Guardant Health, Inc.

Via Business Wire

Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions

February 02, 2026

From Guardant Health, Inc.

Via Business Wire

3 Unpopular Stocks We Think Twice About

February 01, 2026

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps...

Via StockStory

Should You Buy Guardant Health Before Feb. 19? ↗

January 30, 2026

This genomics stock appears to be at an inflection point.

Via The Motley Fool

Topics Earnings

Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

January 29, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

January 22, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform

January 19, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health (NASDAQ:GH): Strongest Q3 Results from the Testing & Diagnostics Services Group

January 14, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Guardant Health (NASDAQ:GH) and its peers.

Via StockStory

CS Diagnostics (OTCQB: CSDX) Advances Infection Control and Oncology Innovation Plus – IVP, SAFX, JTAI, OCG, BMXI Inside

January 14, 2026

Via AB Newswire

Topics Intellectual Property

GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth

January 13, 2026

In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an...

Via MarketMinute

Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization

January 13, 2026

Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that...

Via MarketMinute

Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability

January 12, 2026

On January 12, 2026, the diagnostic sector witnessed a seismic shift as shares of Biodesix (Nasdaq: BDSX) surged more than 40% in early trading, following the release of preliminary full-year 2025...

Via MarketMinute

Topics Artificial Intelligence Death

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results

January 11, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families

January 08, 2026

From Guardant Health, Inc.

Via Business Wire

BTIG's Top Stock Picks for H1 2026: Navigating the New 'Application' Era

January 02, 2026

As the financial markets open for the 2026 calendar year, BTIG has released its highly anticipated "Top Picks" report for the first half of the year, signaling a transition from the speculative fervor...

Via MarketMinute

Topics Artificial Intelligence Economy

1 Growth Stock Set to Flourishand 2 We Avoid

January 01, 2026

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Via StockStory

The Year-End Biotech Chill: Adaptive Biotechnologies Braces for J.P. Morgan Crucible Amid Market Sell-Off

December 30, 2025

As the final trading days of 2025 wind down, the biotechnology sector finds itself caught in a paradoxical "bifurcated" squeeze. While the broader indices have touched record highs this year, a sharp...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

December 29, 2025

From Guardant Health, Inc.

Via Business Wire

Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line ↗

December 28, 2025

Selling shares usually signals doubt, but in this case the math points to something very different happening beneath the surface.

Via The Motley Fool

Topics Regulatory Compliance

Q3 Earnings Roundup: Cardinal Health (NYSE:CAH) And The Rest Of The Healthcare Providers & Services Segment

December 17, 2025

Looking back on healthcare providers & services stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Cardinal Health (NYSE:CAH) and its peers.

Via StockStory

Topics Economy

Q3 Rundown: The Ensign Group (NASDAQ:ENSG) Vs Other Healthcare Providers & Services Stocks

December 15, 2025

Looking back on healthcare providers & services stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including The Ensign Group (NASDAQ:ENSG) and its peers.

Via StockStory

Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.

December 11, 2025

From Guardant Health, Inc.

Via Business Wire

Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy

December 09, 2025

From Guardant Health, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.